CluePoints, a provider of Risk-Based Quality Management (RBQM) and clinical data quality oversight software, has been named a finalist in the Best Contract Research Organization (Specialist Providers) category at the 2026 Scrip Awards.
IQVIA and Veeva Systems has announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be used across IQVIA clinical development studies.
Phesi has launched a new Protocol Complexity analysis module within its AI-powered Trial Accelerator platform that lets sponsors identify and reduce protocol complexity before it drives up cost, timelines and execution risk.
Touchlight’s cell-free, enzymatic dbDNA manufacturing platform underpins the NEOVACC Phase I trial led by The Clatterbridge Cancer Centre and the University of Liverpool.
TrialAssure has announced that its ANONYMIZE platform has been selected by the European Medicines Agency (EMA) as an official anonymisation tool used within the Agency.
SGS has announced it has received formal approval from the Belgian Federal Agency for Nuclear Control (FANC) to resume human ADME (Adsorption, Distribution, Metabolism and Excretion) studies using ¹⁴C-radiolabeled investigational products.
Lindus Health and Quotient Sciences have announced a partnership to enable biotech and pharma sponsors with enhanced patient recruitment for Phase I-IIa clinical studies and a seamless pathway from first-in-human (FIH) to proof-of concept trials.
Phastar, a global specialist biometrics & data science Contract Research Organisation (CRO), has been named as finalists in two categories at the 2025 SCRIP Awards.
Alchemab Therapeutics (Alchemab), a biopharmaceutical company which identifies and develops naturally occurring therapeutic antibodies from resilient individuals, has announced initiation of a Phase 1 first-in-human study of ATLX-1282.
One2Treat, a technology company transforming how the patient voice is integrated into clinical development, has announced the successful completion of a planned seed extension to accelerate its software platform development.
Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered imaging and clinical data curation platform, has announced that it has been selected by Calluna Pharma to support its study.
